Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)

NCT05212922 is registered in ClinicalTrials.gov with Eucure (Beijing) Biopharma Co., Ltd as lead sponsor.

NCT NCT05212922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05212922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of YH001 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
Lead sponsor
Eucure (Beijing) Biopharma Co., Ltd
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2023
Completion date
March 31, 2025
Enrollment
0 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, nsclc stage iiib, nsclc stage iv